Hikma Pharma unveils authorized generic of Xyrem in US
London: Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, has announced it has launched an authorized generic version of Jazz Pharmaceuticals’ Xyrem (sodium oxybate) oral solution CIII. Hikma will have 180 days of marketing exclusivity for its authorized generic product in the US.
Sodium Oxybate oral solution, 0.5 g/mL is a prescription medicine used to treat the following symptoms in people 7 years of age or older with narcolepsy:
- sudden onset of weak or paralyzed muscles (cataplexy)
- excessive daytime sleepiness (EDS)
Jazz Pharmaceuticals reported net sales for Xyrem of $1.3 billion in 2021.
Brian Hoffmann, President of Generics said, “We are pleased to be able to provide the first authorized generic version of Xyrem to patients and health care providers in the US. This launch further expands our diversified portfolio of generic products, and underscores our ability to put Better Health, Within Reach, Every Day for the millions of people who rely on our medicines.”
Hikma Pharma is a British multinational pharma company headquartered in London, UK. The company was founded by Samih Darwazah in 1978. The company manufactures non-branded generic and in-licensed pharmaceutical products.
Read also: Glenmark Specialty, Hikma Pharma launch seasonal allergic rhinitis nasal spray RYALTRIS in US
